Terminé

Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole

+ ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole

Médicament
Qui peut participer

De 1 à 14 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Étude thérapeutique

Phase 4
Interventionnel
Date de début : juillet 2008
Voir le détail du protocole

Résumé

Sponsor principalHaEmek Medical Center, Israel
Dernière mise à jour : 5 septembre 2012
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 juillet 2008

Date à laquelle le premier participant a commencé l'étude.

The study was conducted at the Pediatric Surgery Department at HaEmek Medical Center, Afula, Israel. Included were children age 1-14 years with complicated appendicitis that was defined by one of the followings: 1. Demonstration by abdominal ultrasound and/or computed tomography of appendix perforation and/or peri-appendicular abscess 2. Demonstration by abdominal ultrasound of free fluid, and signs of diffuse peritoneal irritation in the right lower quadrant of the abdomen 3. At surgery performed for suspected non complicated appendicitis. In a patient with perforate appendicitis that was diagnosed at surgery, appendectomy was performed by one of the 4 senior pediatric surgeons on call at the time of the child's admission. Exclusion criteria were: documented allergy to any of the study medications, acute or renal insufficiency at admission, and severe septic shock at admission. Therapeutic approach: After the diagnosis of complicated appendicitis was established, patients were randomly assigned to therapy with either once daily of ceftriaxone and metronidazole or ampicillin, gentamicin and metronidazole. Therapy was change to piperacillin/tazobactam in patients who were still febrile at day 7-10 of the admission (if not given before), based on the clinical situation, and in all febrile patients at 11 day of the admission . All patients had also been treats after inclusion with pain control medications, no oral food or fluid , and intravenous hydration as necessary. Nasogastric tubes were not used routinely. On the fifth admission day patients who were stable, a febrile, could tolerate diet and had Complete blood count within normal limits were discharged home with oral amoxicillin/clavulanate therapy for further 7 days. Follow-up at the admission: CBC and renal and liver function tests were obtained before starting the antibiotic treatment and repeated on day 4 in all patients. In the group treated with AGM, serum trough gentamicin concentration was drawn before the fourth dose with normal level considered as < 2 mcg/ml. Other blood studies were performed based on the discretion of the attending physician based on the patient's clinical status. For patients who were either febrile or had leukocytosis, at day 5 of therapy abdominal ultrasound was obtained to assess for the presence of an abscess. Patients in whom abscesses were delectated undergone per coetaneous drainage (when possible). The original antibiotic regimen was either continued or changed to piperacillin/tazobactam based on the clinical situation. Patients, in whom appendectomy had not been done at admission, were readmitted for appendectomy at 6 weeks. All patients had been followed for a year since the admission for signs of intra abdominal complication such: repeat abscess formation, repeat admission, obstruction etc. Data collection: Data were recorded were: patient's age, weight, gender, maximum daily temperature, duration of fever, results of complete blood count, renal and liver function tests, gentamicin levels (where applicable), intra abdominal complications and duration of hospitalization. The outcome variables included maximum daily temperatures for each of the first 10 postoperative days, time to initial oral intake, length of hospitalization, length of antibiotic therapy, abscess formation rate, need to change antibiotic regimen, wound infection rate, and any abnormal findings during the follow-up visits. Statistical analysis: Since data in the literature show that there is no difference of the length of stay in between the 2 regimens (in children with complicated appendicitis following operation), and most studies included relatively low number of patients, no power analysis was calculated. The difference between various parameters in the two treatment groups were assessed by 2 independent sample T tests or Fisher exact tests for categorical data and 2 independent sample t test or the Mann Whitney test for continuous data. Descriptive statistics were calculated as mean ± SD.

Sponsor principalHaEmek Medical Center, Israel
Dernière mise à jour : 5 septembre 2012
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

43 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Traitement

Cette étude teste un ou plusieurs traitements pour évaluer leur efficacité contre une maladie ou un problème de santé spécifique. L'objectif est de voir si un nouveau médicament ou une thérapie fonctionne mieux, ou provoque moins d'effets secondaires que les options existantes.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

De 1 à 14 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Critères

Inclusion Criteria: Children age 1-14 years CA that was defined by one of the followings: Demonstration by abdominal ultrasound (US) and/or computed tomography (CT) of appendix perforation and/or peri-appendicular abscess Demonstration by abdominal ultrasound (US) of free fluid, and signs of diffuse peritoneal irritation in the right lower quadrant of the abdomen 3 Exclusion Criteria: Documented allergy to any of the study medications, acute or renal insufficiency at admission, and severe septic shock at admission.

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

2 groupes d'intervention sont désignés dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

Expérimental
Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.

Groupe II

Comparateur actif
Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Pediatric Surgery Department, HaEmek Medical Center

Afula, IsraelOuvrir Pediatric Surgery Department, HaEmek Medical Center dans Google Maps
Terminé1 Centres d'Étude